Results 31 to 40 of about 131 (88)

Transcriptome-wide changes in gene expression, splicing, and lncRNAs in response to a live attenuated dengue virus vaccine

Cell Reports, 2022
Summary: The tetravalent dengue vaccine candidate, TAK-003, induces a functional antibody response, but the titers of antibodies against the four serotypes of the dengue virus (DENV) can vary.
Eun-Young Kim, Yan Che, Hansi J. Dean, Ramon Lorenzo-Redondo, Michael Stewart, Caroline K. Keller, Daniel Whorf, Dawson Mills, Nikita N. Dulin, Tiffany Kim, Megan Votoupal, Miriam Walter, Ana Fernandez-Sesma, Heejin Kim, Steven M. Wolinsky   +14 more
doaj   +1 more source

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Frontiers in Immunology, 2022
Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas.
Jue Hou, Weijian Ye, Jianzhu Chen, Jianzhu Chen   +3 more
doaj   +1 more source

The evolution of dengue fever trends in the Central-West Region of Brazil: An 11-year analysis of incidence data from 2013 to 2023 in Mato Grosso do Sul

International Journal of Infectious Diseases
Objectives: In 2024, Dourados, Mato Grosso do Sul, Brazil became the first municipality to launch a mass dengue vaccination campaign in individuals aged 4-60 years.
Cristina Valencia, Benedetta Ghezzi, Roberto Dias de Oliveira, Daniel Tsuha, Waldno Lucena Júnior, Alberta Di Pasquale, Morgan Mc Namara, Juliana Senra, Denise Abud, Julio Croda   +9 more
doaj   +1 more source

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database

Frontiers in Pharmacology
IntroductionDengue is one of the major global public health burden, particularly in endemic regions. CYD-TDV and TAK-003 are the currently licensed live attenuated tetravalent dengue vaccines, differing in serostatus indication, age range, and ...
Viviana Maria Gianguzzo, Michelangelo Rottura, Federica Maria Sacco, Matthew Gavino Donadu, Giuseppina Sanna, Natasha Irrera, Egidio Imbalzano, Vincenzo Arcoraci, Giuseppinella Melita, Ylenia Marino, Sara Manti, Giovanni Pallio   +11 more
doaj   +1 more source

Comparison of Neutralizing Dengue Virus B Cell Epitopes and Protective T Cell Epitopes With Those in Three Main Dengue Virus Vaccines

Frontiers in Immunology, 2021
The four serotypes of Dengue virus (DENV1-4) are arboviruses (arthropod-borne viruses) that belong to the Flavivirus genus, Flaviviridae family. They are the causative agents of an infectious disease called dengue, an important global public health ...
Josilene Ramos Pinheiro, Josilene Ramos Pinheiro, Esther Camilo dos Reis, Rayane da Silva Oliveira Souza, Ana Luíza Silva Rocha, Lincoln Suesdek, Vasco Azevedo, Sandeep Tiwari, Beatriz Gonçalves Silva Rocha, Alexander Birbrair, Erick Carvalho Méndez, Wilson Barros Luiz, Jaime Henrique Amorim, Jaime Henrique Amorim   +13 more
doaj   +1 more source

PP77 Cost-Effectiveness Of The Dengue Vaccine (TAK-003) In Brazil

International Journal of Technology Assessment in Health Care
IntroductionDengue is an arbovirus that causes an acute febrile illness transmitted by the Aedes aegypti mosquito. The TAK-003 vaccine produced with Vero cells using recombinant DNA technology from the live and attenuated virus was approved by the Brazilian regulatory agency for preventing dengue infection, regardless of previous infection.MethodsA ...
Fernandes, Ricardo, da Costa, Márcia Gisele, Tura, Bernardo, Barros, Bruno, Santos, Marisa   +4 more
openaire   +1 more source

Travel medicine providers’ opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan

Human Vaccines & Immunotherapeutics
TAK-003 is a dengue vaccine introduced in dengue-endemic countries and considered for travelers. Although not yet approved in Japan, inquiries from travelers are increasing.
Atsuko Fukunishi, Masaki Machida, Shinji Fukushima, Shigeru Inoue   +3 more
doaj   +1 more source

The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study

Vaccines, 2020
There is a growing public health need for effective preventive interventions against dengue, and a safe, effective and affordable dengue vaccine against the four serotypes would be a significant achievement for disease prevention and control.
Maíra Aguiar, Nico Stollenwerk
doaj   +1 more source

Retrospective analysis of one year of passive safety surveillance data following implementation of the dengue vaccine, Qdenga® (TAK-003) at private vaccination centers, in Buenos Aires, Argentina

Vaccine: X
Background: Dengue vaccine Qdenga® has been available in Argentina since November 2023. This study aimed to evaluate adverse events following immunization (AEFI) in individuals vaccinated with Qdenga® in private centers in the metropolitan area of Buenos
Vanesa Edelvais Castellano, MD, Sofìa Diana Menéndez, Jimena Ochoa, MD, Fernando Burgos, MD, Fernando Fernadez, MD, Romina Gigliotti, MD, Mariano Díaz, MD, Pablo Bonvehí, MD   +7 more
doaj   +1 more source

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults

Vaccine, 2023
We conducted a trial to demonstrate immunogenic equivalence of three consecutive manufacturing lots of Takeda's tetravalent dengue vaccine candidate, TAK-003, and further assessed its safety and reactogenicity.Healthy US adults (n = 923) randomized 2:2:2:1 to four groups received two doses of one of three TAK-003 lots or placebo on Days 0 and 90, with ...
Vianney Tricou, Peter J. Winkle, Leslie M. Tharenos, Martina Rauscher, Ian Escudero, Elaine Hoffman, Inge LeFevre, Astrid Borkowski, Derek Wallace   +8 more
openaire   +2 more sources